Compared with the major trials (e.g. 4D, AURORA and Study of Heart and Renal Protection [SHARP]), our cohort had lower event rate older patients, lower serum albumin levels, fewer patients with diabetic nephropathy and lower incidence of CVEs—all factors that may help explain the null results related to the time-dependent phosphate levels. This evidence concerns the gene ALB and diabetic kidney disease.